F. Moiseenko, N. Volkov, A. Zhabina, M. Stepanova, N. A. .. Rjsev, V. Klimenko, A. Myslik, E. Artemieva, N. H. Abduloeva, V. Egorenkov, V. Moiseyenko
{"title":"非小细胞肺癌tki治疗期间egfr突变ctdna纵向评价的预后意义","authors":"F. Moiseenko, N. Volkov, A. Zhabina, M. Stepanova, N. A. .. Rjsev, V. Klimenko, A. Myslik, E. Artemieva, N. H. Abduloeva, V. Egorenkov, V. Moiseyenko","doi":"10.31917/2104296","DOIUrl":null,"url":null,"abstract":"Detection of EGFR mutations in tumor tissue is the gold standard for prescribing tyrosine kinase inhibitor therapy.However even in the same molecularly defined population effect of the treatment, response duration and survival might differ significantly. We did a prospective clinical trial to assess ctDNA-based EGFR mutations as a prognostic marker for patients with lung adenocarcinoma receiving TKI as first-line treatment.","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"42 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic significance of longitudinal evaluation on egfr mutant ctdna during tki treatment in nsclc\",\"authors\":\"F. Moiseenko, N. Volkov, A. Zhabina, M. Stepanova, N. A. .. Rjsev, V. Klimenko, A. Myslik, E. Artemieva, N. H. Abduloeva, V. Egorenkov, V. Moiseyenko\",\"doi\":\"10.31917/2104296\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Detection of EGFR mutations in tumor tissue is the gold standard for prescribing tyrosine kinase inhibitor therapy.However even in the same molecularly defined population effect of the treatment, response duration and survival might differ significantly. We did a prospective clinical trial to assess ctDNA-based EGFR mutations as a prognostic marker for patients with lung adenocarcinoma receiving TKI as first-line treatment.\",\"PeriodicalId\":101072,\"journal\":{\"name\":\"Reports of Practical Oncology\",\"volume\":\"42 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reports of Practical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31917/2104296\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Practical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31917/2104296","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prognostic significance of longitudinal evaluation on egfr mutant ctdna during tki treatment in nsclc
Detection of EGFR mutations in tumor tissue is the gold standard for prescribing tyrosine kinase inhibitor therapy.However even in the same molecularly defined population effect of the treatment, response duration and survival might differ significantly. We did a prospective clinical trial to assess ctDNA-based EGFR mutations as a prognostic marker for patients with lung adenocarcinoma receiving TKI as first-line treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
